ResMed Inc. Chairman and Chief Executive Officer Michael J. Farrell reported a same-day stock option exercise and sale involving ResMed common stock on July 7, 2026. Farrell exercised options to acquire 4,991 shares of ResMed common stock at an exercise price of $146.34 per share. The option exercise was reported with transaction code “M,” which is used for the exercise or conversion of derivative securities. The exercise cost for those shares was approximately $730,383 before taxes and fees. The filing notes that the related options vest one-third per year, and that the date shown for the options represents the date they first became exercisable. On the same date, Farrell sold shares of ResMed common stock under transaction code “S.” The sale was executed under a Rule 10b5-1 trading plan that Farrell had adopted on October 31, 2024. The reported weighted-average sale price was $218.5475 per share, with the actual trades occurring across a price range of $216.772 to $219.700. If the sale matched the 4,991 shares acquired through the option exercise, the gross proceeds would have been approximately $1.09 million. The filing indicates Farrell’s ownership increased to 471,.